Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Aclaris Therapeutics, retaining the price target of $16.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ram Selvaraju has given his Buy rating due to a combination of factors that highlight Aclaris Therapeutics’ promising future. The company is positioned to achieve significant clinical milestones with its diverse portfolio of small molecule and biologic assets. Notably, Aclaris is advancing its anti-TSLP monoclonal antibody, bosakitug, into a Phase 2 trial for atopic dermatitis, with results expected in the second half of 2026. Additionally, the company is progressing with ATI-052, a bispecific antibody, and ATI-2138, a dual inhibitor, both of which are expected to reach important clinical stages in the coming years.
Financially, Aclaris reported a net loss for the third quarter of 2025 that aligns with expectations, and it maintains a strong cash position to support its operations through multiple key value inflection points. The presentation of positive clinical results for ATI-2138 at a recent dermatology conference further underscores the potential of its pipeline. These developments, combined with the company’s strategic financial management, underpin Selvaraju’s confidence in Aclaris’ growth prospects, leading to the reiterated Buy rating and a 12-month price target of $16.